Jounce Therapeutics to Participate in Fireside Chat at the Raymond James Human Health Innovation Conference
June 14 2021 - 8:00AM
Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company
focused on the discovery and development of novel cancer
immunotherapies and predictive biomarkers, today announced that
Richard Murray, Ph.D., chief executive officer and president will
participate in a fireside chat at the Raymond James Human Health
Innovation Conference, taking place virtually on Monday, June 21,
2021 at 12:40 p.m. ET.
A webcast of the fireside chat will be available by visiting
“Events and Presentations” in the Investors and Media section of
Jounce’s website at www.jouncetx.com. A replay of the webcast will
be archived for 30 days following the presentation.
About Jounce TherapeuticsJounce Therapeutics,
Inc. is a clinical-stage immunotherapy company dedicated to
transforming the treatment of cancer by developing therapies that
enable the immune system to attack tumors and provide long-lasting
benefits to patients through a biomarker-driven approach. Jounce
currently has multiple development stage programs ongoing while
simultaneously advancing additional early-stage assets from its
robust discovery engine based on its Translational Science
Platform. Jounce’s highest priority program, JTX-8064, is a LILRB2
(ILT4) receptor antagonist shown to reprogram immune-suppressive
tumor associated macrophages to an anti-tumor state in preclinical
studies. A Phase 1 clinical trial, named INNATE, of JTX-8064 as a
monotherapy and in combination with pimivalimab (formerly
JTX-4014), Jounce’s internal PD-1 inhibitor, is currently enrolling
patients with advanced solid tumors. Jounce’s most advanced product
candidate, vopratelimab, is a monoclonal antibody that binds to and
activates ICOS, and is currently being studied in the SELECT Phase
2 trial. Pimivalimab is a PD-1 inhibitor intended for combination
use in the INNATE and SELECT trials and with Jounce’s broader
pipeline. Additionally, Jounce exclusively licensed worldwide
rights to JTX-1811, a monoclonal antibody targeting CCR8 and
designed to selectively deplete T regulatory cells in the tumor
microenvironment, to Gilead Sciences, Inc. For more information,
please visit www.jouncetx.com.
Investor and Media Contacts:
Mark YoreJounce Therapeutics,
Inc.+1-857-200-1255myore@jouncetx.com
Julie SeidelStern Investor
Relations+1-212-362-1200Julie.Seidel@sternir.com
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Jounce Therapeutics (NASDAQ:JNCE)
Historical Stock Chart
From Sep 2023 to Sep 2024